ArticleNature communications2022
BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 22 citations in OpenAlex.
- Fisetin Induces Apoptosis and Inhibits Migration of Melanoma Cells by Suppressing Glycolytic Metabolism via PKM2 Inhibition.Annals of dermatology · 2026Article
- Orchestrating glucose metabolism: PFKFB2 as a signal-integrating conductor in homeostasis and disease.The Journal of biological chemistry · 2026Review
- MAPK Inhibitor-Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities.Cancer science · 2026Review
- Parallel adaptation to geothermally-warmed habitats due to common structural variation and functional developmental pathways.Nature communications · 2026Article
- Simvastatin reprograms lipid metabolism in B16.F10 melanoma cells to favor an early resistant phenotype.Scientific reports · 2026Article
- Lactate metabolism and lactylation in cancer: from pathogenesis to therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Article
- Lipidomics in Melanoma: Insights into Disease Progression and Therapeutical Targets.International journal of molecular sciences · 2026Review
- Melanoma: Pathogenesis and Targeted Therapy.MedComm · 2026Review
- Role and Molecular Mechanisms of Aerobic Glycolysis in Gastrointestinal Tumors.Journal of Cancer · 2026Review
- Isoliquiritigenin Impedes Breast Cancer Progression through PITX1-PFKP-Mediated Glycolysis Reprogramming.Oncology research · 2026Article
- Metabolic reprogramming as a driver of immune escape in melanoma: implications for immunotherapy.Frontiers in immunology · 2026Review
- Dihydrotanshinone I Targets PGAM1 to Induce SYVN1-Mediated Ubiquitination and Suppress Glycolysis in Hepatocellular Carcinoma.Phytotherapy research : PTR · 2025Article
- Metabolic reprogramming in melanoma therapy.Cell death discovery · 2025Review
- Metabolic Reprogramming in Melanoma: An Epigenetic Point of View.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAFOncogene · 2025Article
- Exploiting Paradoxical Activation of Oncogenic MAPK Signaling by Targeting Mitochondria to SensitizeInternational journal of molecular sciences · 2025Article
- Harnessing the Power of Metabolomics for Precision Oncology: Current Advances and Future Directions.Cells · 2025Review
- Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma.Cancer treatment reviews · 2024Review
- Proteomic Analysis Highlights the Impact of the Sphingolipid Metabolizing Enzyme β-Galactosylceramidase on Mitochondrial Plasticity in Human Melanoma.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 3 countries.
Kimberley McGrailBiomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.ORCID 0000-0001-7227-7306
Paula Granado-MartínezBiomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.ORCID 0000-0002-7765-8914
Rosaura Esteve-PuigBiomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.ORCID 0000-0003-0547-1752
Sara García-OrtegaBiomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.ORCID 0000-0002-4404-5441
Yuxin DingBiomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.ORCID 0000-0003-1384-7967
Sara Sánchez-RedondoBiomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.
Berta FerrerBiomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.
Javier Hernandez-LosaAnatomy Pathology Department, Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.ORCID 0000-0003-1526-3201
Francesc CanalsProteomics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, 08035, Spain.
Anna ManzanoDepartment of Physiological Sciences, University of Barcelona, Bellvitge Biomedical Research Institute, Barcelona, Spain.ORCID 0000-0002-9106-3132
Aura Navarro-SabatéDepartment of Physiological Sciences, University of Barcelona, Bellvitge Biomedical Research Institute, Barcelona, Spain.ORCID 0000-0002-8286-9732
Ramón BartronsDepartment of Physiological Sciences, University of Barcelona, Bellvitge Biomedical Research Institute, Barcelona, Spain.
Oscar YanesUniversitat Rovira i Virgili, Department of Electronic Engineering, IISPV, Tarragona, Spain.ORCID 0000-0003-3695-7157
Mileidys Pérez-AleaBiomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.
Eva Muñoz-CouseloBiomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.
Vicenç Garcia-PatosBiomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain.ORCID 0000-0003-1654-6035
Juan A RecioBiomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Hospital Barcelona-UAB, Barcelona, 08035, Spain. juan.recio@vhir.org.ORCID 0000-0002-7320-3832
Vall d'Hebron Institut de Recerca · ESInstitut d'Investigació Biomédica de Bellvitge · ESHebron University · PSBarcelona Graduate School of Mathematics · ESInstituto de Salud Carlos III · ESSpanish National Cancer Research Centre · ESVall d'Hebron Hospital Universitari · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
NRAS-mutated melanoma lacks a specific line of treatment. Metabolic reprogramming is considered a novel target to control cancer; however, NRAS-oncogene contribution to this cancer hallmark is mostly unknown. Here, we show that NRAS
Indexed as
MelanomaProto-Oncogene Proteins B-rafCell Line, TumorGlucoseGlycolysisGTP PhosphohydrolasesHumansMembrane ProteinsMutationPhosphofructokinase-2SorafenibStress, PhysiologicalBRAF protein, humanGlucoseGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanPFKFB2 protein, humanPhosphofructokinase-2Proto-Oncogene Proteins B-rafSorafenib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.